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Introduction
Prostate cancer (PC) and its treatment affect 
patients’ quality of life across biological, psycho-
logical, and social domains including sexual 
health (Chung and Brock, 2013). Changes in 
sexual functioning such as altered libido and 
erectile dysfunction are common consequences 
of treatment (Sanda et al., 2008). In addition to 
functionality, sexual bother or psychological dis-
tress related to sexual problems can also occur 
after PC treatment and might be associated with 
relational disruption with intimate partners. With 
early-stage disease, greater sexual dysfunction, 
younger age, and using erectile aids are associ-
ated with higher sexual bother (Gacci et al., 
2009). Resultantly, sexual dysfunction and 
related psychological distress constitute daily 
and chronic stress that interferes with adjustment 
across the PC continuum.
The hypothalamic–pituitary–adrenal (HPA) 
axis is a primary system involved in the physi-
ological response to stress and is stimulated by 
physical or psychological stressors like those 
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endured with sexual dysfunction. Activation 
of the HPA axis signals a cascade of hormones 
including glucocorticoids such as cortisol, 
which exert immunosuppressive effects, regu-
late metabolic processes, and provide negative 
feedback to rapidly resume physiological 
homeostasis (Gaffey et al., 2016). In healthy 
adults, cortisol peaks 30–45 minutes after 
morning waking and reaches a nadir in the 
evening (Clow et al., 2010). Altered cortisol 
patterns (e.g. elevated afternoon cortisol), 
which are signatures of HPA axis dysregula-
tion, have been observed in PC patients who 
report more stress, higher depressive symp-
toms, and lower quality of life (Hoyt et al., 
2016; Hsiao et al., 2011; Sharpley et al., 2016). 
Despite the significant impact and chronicity 
of sexual problems after treatment, biobehav-
ioral mechanisms (e.g. neuroendocrine stress 
dynamics) underlying impaired sexual func-
tion and distress are not well delineated. That 
is, if physiological stress responses are associ-
ated with sexual quality of life after PC, are 
such responses underlying both functional and 
emotional domains?
In non-cancer samples, men with erectile 
dysfunction display elevated levels of cortisol, 
norepinephrine, and inflammatory markers 
(including interleukin (IL)-6 and C-reactive 
protein (CRP)), as well as testosterone deficien-
cies. Dysregulation in cortisol rhythm might 
further inhibit male sexual arousal (Granata 
et al., 1995; Guigliano et al., 2004; Kobori 
et al., 2009; Sansone et al., 2014; Uckert et al., 
2003). Elucidating biobehavioral mechanisms 
that distinguish PC patients’ sexual dysfunction 
and sexual bother will help reveal the etiology 
of men’s sexual quality of life and guide recom-
mendations for stress regulation.
The aim of this study was to determine 
whether sexual functioning or sexual bother is 
associated with diurnal cortisol. It was hypoth-
esized that poorer sexual functioning and 
greater sexual bother would be associated with 
indices of cortisol dysregulation (both function 
and bother), including a flatter diurnal slope, 
lower diurnal output, and lower morning corti-
sol rise.
Methods
Participants
A total of 66 men (M age = 65.8 years; standard 
deviation (SD) = 9.0) who underwent radical 
prostatectomy or radiation therapy for localized 
PC within the prior 2 years were recruited via 
physician/clinic referrals, community outreach, 
and institutional tumor registry. Participants 
were excluded for medical comorbidities (e.g. 
active infection) or medications (e.g. steroids) 
that could confound cortisol evaluation; those 
with severe mental illness or regular smokers 
were also excluded.
All procedures were approved by the 
University of California–Los Angeles (UCLA) 
Institutional Review Board.
Measures
Sexual functioning and bother. The University of 
California–Los Angeles Prostate Cancer Index 
(UCLA-PCI) is a self-report measure of sexual 
functioning and sexual bother over the past 
4 weeks (Litwin et al., 1998). The UCLA-PCI is 
a 20-item disease-specific questionnaire with 
strong psychometric properties. Each domain is 
scored from 0 to 100; higher scores correspond 
with better functioning. This study used stand-
ard scoring procedures, including the single 
sexual bother item (i.e. Overall, how big a prob-
lem has your sexual function been for you?) and 
the sexual functioning subscale (Cronbach’s 
alpha = .91). The sexual functioning subscale 
includes questions about sexual desire, engage-
ment in sexual activity, ability to reach orgasm, 
and erection quality and frequency.
Negative affect. The Positive and Negative Affect 
Schedule (PANAS) was used to assess negative 
affect. The scale includes 10 items measuring 
negative affective states experienced during the 
past few weeks (Watson et al., 1988; α = .92).
Diurnal cortisol was assessed with saliva 
samples collected at home using Salivette collec-
tion tubes (Sarstedt, Inc., Nümbrecht, Germany). 
Participants collected saliva upon awakening 
(morning), 30 minutes post-awakening, 8 hours 
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post-awakening (afternoon), and at bedtime on 
three consecutive days. They were instructed not 
to eat, drink, or brush teeth 20 minutes before 
sampling. Participants self-reported compliance 
via use of a call-in line at the time of each collec-
tion and daily compliance log. Salivettes were 
stored in a −20°C freezer until analyzed. 
Concentrations of salivary free cortisol were 
measured in duplicate using a commercially 
available chemiluminescence-immunoassay at 
the TUD Biopsychology Laboratory in Dresden, 
Germany. Assay sensitivity was measured to be 
0.015 µg/dL. The lower detection limit was 
0.41 nmol/L, and inter-assay and intra-assay 
coefficients of variance were <10 percent.
Three cortisol indices were examined: diurnal 
cortisol slope, area under the curve with respect 
to ground (AUCg), and the cortisol awakening 
response (CAR). Diurnal slope reflects the rate 
of decrease from highest morning sample to the 
evening sample. Greater slope values reflect 
more rapid declines in cortisol levels (lower 
evening values), whereas smaller values reflect 
flatter diurnal rhythms (higher evening values). 
To examine overall cortisol volume, AUCg 
across day was computed using the trapezoidal 
method based on hours after awakening 
(Pruessner et al., 2003). The 30-minute measure 
was excluded from this calculation as the early 
morning increase of cortisol is relatively inde-
pendent from overall cortisol volume (Chida and 
Steptoe, 2003). Finally, CAR is assessed by the 
absolute cortisol increase from awakening (aver-
aged across days) to the second cortisol sample 
(30-minute post-awakening; averaged across 
days). These parameters characterize the distinc-
tive circadian pattern of cortisol secretion but 
likely represent different aspects of HPA axis 
function and may be independently regulated 
(Clow et al., 2010).
Participants self-reported demographic and 
disease-related variables.
Data analysis
Hierarchical linear modeling (HLM; HLM 7.0 
statistical software program, Supplemental 
Security Income (SSI) Inc.) was used to 
examine change in diurnal rhythm over time on 
an individual basis (i.e. cortisol levels across the 
day; Bryk and Raudenbush, 1992). Slope of the 
diurnal change in cortisol levels was calculated 
by regressing cortisol values on time of day 
(excluding 30 minutes post-awakening) for each 
collection day. Cortisol observation times were 
entered as Level 1 units in the analyses. Sexual 
functioning, sexual bother, and covariates were 
entered at Level 2. Multiple linear regression 
was used to test hypotheses related to CAR and 
total daily cortisol output. Cortisol parameters 
were separately regressed on sexual functioning 
and sexual bother. In post hoc tests, analyses 
were repeated to control for negative affect to 
consider the impact of stress-related and/or 
depressive emotions. All analyses included par-
ticipant age and body mass index as covariates.
Results
Participants were mostly White (85%), married/
partnered (89%), and had at least a 4-year college 
degree (59%). Most men underwent radical pros-
tatectomy (71%) and 32 percent received radia-
tion treatment, with a small percentage receiving 
both. The average Gleason score was 5.7 
(SD = 1.4). Men reported sexual functioning 
(M = 41.50, SD = 28.19) and sexual bother 
(M = 57.31, SD = 37.69) similar to samples of men 
treated for localized disease (Gore et al., 2009).
Sexual function and bother and 
diurnal cortisol indices
Diurnal cortisol slope. HLM revealed that higher 
sexual bother (t = −2.55, p = .01), but not sexual 
functioning (t = .53, p = .60), was associated 
with steeper cortisol slope. The observed corti-
sol pattern is depicted in Figure 1. Analyses 
controlling for negative affect did not signifi-
cantly change the strength or direction of the 
observed relationships and negative affect did 
not interact with sexual functioning.
Awakening response. Multiple regression analy-
ses revealed that better sexual functioning 
(t = .40, p = .04), but not sexual bother (t = −.37, 
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p = .08), was significantly associated with CAR. 
In post hoc analyses controlling for negative 
affect, sexual functioning was not significant.
Daily cortisol output. Daily cortisol output (aver-
aged across 3 days) was 1.37 ng/dL (SD = 0.69). 
Cortisol data were log-transformed to control 
for skewness. Neither sexual functioning 
(t = −.07, p = .45) nor sexual bother was signifi-
cantly associated with daily cortisol output 
(t = .20, p = .62).
Discussion
Results support a relationship between dysregu-
lation in HPA activity and sexual quality of life 
after PC treatment. Men who were more both-
ered by sexual problems exhibited a flatter cor-
tisol slope, with a seemingly blunted morning 
cortisol level. Flatter slope across the day might 
reflect a constellation of behavioral symptoms 
that include depression, fatigue, avoidance, 
and/or poor sleep (Ancelin et al., 2017; Hoyt 
et al., 2014, 2016; Schmidt et al., 2016). At the 
same time, sexual function scores were associ-
ated with CAR, whereby men with poorer 
functioning had smaller morning rises than 
those with better function.
This is the first known study to document a 
relationship of CAR and sexual function. CAR 
reflects the rapid increase in cortisol that occurs 
30–45 minutes after awakening. However, its 
precise function is not well established. It may 
be uniquely related to health outcomes from 
other cortisol indices (Golden et al., 2013). 
CAR may be linked to hippocampal activation 
to prepare for anticipated stress (Clow et al., 
2010). The loss of the significant effect of sex-
ual function on CAR when controlling for nega-
tive affect further supports that this relationship 
may be mediated by an emotional response 
related to anticipatory stress. Loss of sexual 
interest was associated with lower ambient 
plasma cortisol in veterans with post-traumatic 
stress disorder (PTSD; Lehrner et al., 2016). 
Future studies should isolate relationships of 
cortisol patterns with domains of sexual func-
tioning (e.g. libido vs erectile function).
Increasing clinical attention is being given to 
biobehavioral models of cancer adjustment, stress, 
and disease course, and dysregulation in the HPA 
axis is associated with poorer psychological 
Figure 1. Diurnal cortisol patterns plotted at high (above the median) and low (below the median) levels 
of sexual bother (median = 38.63). Higher sexual bother was associated with lower morning cortisol levels 
and overall flatter diurnal slope.
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adjustment and cancer progression (Armaiz-Pena 
et al., 2013; Fagundes et al., 2017; Giese-Davis 
et al., 2006). Such biological responses, co-occur-
ring with psychological stress, also have significant 
potential to affect engagement in treatment provid-
ing an adjunctive behavioral pathway (Karvinen 
et al., 2013). Future research should explore HPA 
involvement in adherence to penile rehabilitation 
and injection protocols. Interventions shown to alter 
HPA axis activity (e.g. physical activity, cognitive-
behavioral stress management) may offer contribu-
tions to sexual rehabilitation after PC.
In this study, measurements were made at a 
single point in time. Future work that incorpo-
rates repeated measurements of HPA axis activity 
will better elucidate its mechanistic role and con-
tribute to the specificity of the observed effect. To 
enhance clinical relevance, understanding the 
impact of sexual bother at more targeted times in 
the cancer trajectory will be useful. Notably, sex-
ual bother was measured with a single item. 
Although this item is a widely used, validated 
assessment of sexual bother, a multi-dimensional 
tool might better measure cognitive-emotional 
responses. Finally, post hoc power analyses 
revealed adequate power to test the primary 
hypotheses (>.80), but not differences between 
radiation and surgical patients. Distinguishing 
patient subgroups, as well as inclusion of non-
cancer controls, is an important next step.
Despite these limitations, this is the first 
study to show an association between sexual 
well-being and cortisol in PC survivors. 
Psychosexual assessment, patient education, 
and behavioral interventions to reduce psycho-
logical bother with sexual problems may be 
valuable in maintaining patient engagement and 
physiological regulation after PC treatment.
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